Carcinogenesis Advance Access originally published online on November 4, 2006
Carcinogenesis 2007 28(1):13-20; doi:10.1093/carcin/bgl214
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
p53-based cancer therapies: is defective p53 the Achilles heel of the tumor?
Department of Pharmacology and Toxicology, Dartmouth Medical School and Norris Cotton Cancer Center One Medical Center Drive, Rubin Building Level 6, Lebanon, NH 03756, UK
*To whom correspondence should be addressed. Tel: +44 603 653 9981; Fax: +44 603 653 9952; Email: alan.r.eastman{at}dartmouth.edu
The tumor suppressor protein p53 plays a pivotal role in the DNA damage response and is defective in >50% of human tumors, which has generated substantial interest in developing p53-targeted cancer therapies. Various therapeutic rationales targeting p53 are currently under investigation including attempts to both activate and inhibit p53. Elevation of p53 can be achieved by either reintroducing an exogenous p53 gene or by blocking its association with its negative regulator hDM2. An alternate approach involves reverting mutant p53 to its wild-type conformation. Inhibition of p53 activity can be achieved either by preventing p53-mediated gene expression or by inhibiting the mitochondrial pro-apoptotic interactions of p53. These approaches are based on the concept that activation of p53 in a tumor is cytotoxic while inhibition of p53 in normal cells will protect the patient. However, activation of p53 also induces cell cycle arrest that can protect most normal cells from DNA damage, and this is the reason why many p53-defective tumors are more sensitive to DNA damage. The development of cell cycle checkpoint inhibitors to abrogate DNA damage-induced arrest builds on this observation as p53-defective cells appear particularly sensitive. Thus, normal cells are protected from premature entry into mitosis and the subsequent mitotic catastrophe induced by checkpoint inhibitors, while p53-defective tumor cells are destroyed. These contradictory approaches must be resolved if we are to take full advantage of the frequent p53 defect in tumors.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. A. Levesque, A. A. Fanous, A. Poh, and A. Eastman Defective p53 signaling in p53 wild-type tumors attenuates p21waf1 induction and cyclin B repression rendering them sensitive to Chk1 inhibitors that abrogate DNA damage-induced S and G2 arrest Mol. Cancer Ther., February 1, 2008; 7(2): 252 - 262. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Alvarez-Gonzalez Genomic Maintenance: The p53 Poly(ADP-ribosyl)ation Connection Sci. Signal., December 4, 2007; 2007(415): pe68 - pe68. [Abstract] [Full Text] [PDF]
|
|